Ontunisertib (AGMB-129)
Phase 2Fibrostenosing Crohn's Disease (FSCD)
Data readoutStock, pipeline and biotech catalyst intelligence
Clinical portfolio
| Asset | Indication | Stage | Milestone | Signals ? |
|---|---|---|---|---|
| Ontunisertib (AGMB-129) | Fibrostenosing Crohn's Disease (FSCD) | Phase 2 | Dec 31, 2026 | — |
| AGMB-447 | Idiopathic pulmonary fibrosis (IPF) | Phase 1b | Dec 31, 2026 | — |
Upcoming milestones
Fibrostenosing Crohn's Disease (FSCD)
Data readoutCompany profile
AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials. It also develops AGMB-101, a HGF-mimetic monoclonal antibody that acts through agonism or stimulation of the MET receptor and has demonstrated antifibrotic and regenerative activity in preclinical models. The company was incorporated in 2017 and is headquartered in Antwerp, Belgium.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
Idiopathic pulmonary fibrosis (IPF)
Data readout